S&P 500   3,336.40 (-0.45%)
DOW   27,417.67 (-0.60%)
QQQ   276.54 (-0.24%)
AAPL   114.01 (-0.83%)
MSFT   208.09 (-0.64%)
FB   259.34 (+0.98%)
GOOGL   1,460.63 (+0.14%)
AMZN   3,165.96 (-0.25%)
TSLA   426.30 (+1.21%)
NVDA   530.77 (+1.80%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.78 (+2.13%)
GE   6.08 (-1.94%)
AMD   81.90 (+3.04%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.13 (-1.15%)
NFLX   493.46 (+0.57%)
DIS   124.12 (-1.48%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,336.40 (-0.45%)
DOW   27,417.67 (-0.60%)
QQQ   276.54 (-0.24%)
AAPL   114.01 (-0.83%)
MSFT   208.09 (-0.64%)
FB   259.34 (+0.98%)
GOOGL   1,460.63 (+0.14%)
AMZN   3,165.96 (-0.25%)
TSLA   426.30 (+1.21%)
NVDA   530.77 (+1.80%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.78 (+2.13%)
GE   6.08 (-1.94%)
AMD   81.90 (+3.04%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.13 (-1.15%)
NFLX   493.46 (+0.57%)
DIS   124.12 (-1.48%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,336.40 (-0.45%)
DOW   27,417.67 (-0.60%)
QQQ   276.54 (-0.24%)
AAPL   114.01 (-0.83%)
MSFT   208.09 (-0.64%)
FB   259.34 (+0.98%)
GOOGL   1,460.63 (+0.14%)
AMZN   3,165.96 (-0.25%)
TSLA   426.30 (+1.21%)
NVDA   530.77 (+1.80%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.78 (+2.13%)
GE   6.08 (-1.94%)
AMD   81.90 (+3.04%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.13 (-1.15%)
NFLX   493.46 (+0.57%)
DIS   124.12 (-1.48%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,336.40 (-0.45%)
DOW   27,417.67 (-0.60%)
QQQ   276.54 (-0.24%)
AAPL   114.01 (-0.83%)
MSFT   208.09 (-0.64%)
FB   259.34 (+0.98%)
GOOGL   1,460.63 (+0.14%)
AMZN   3,165.96 (-0.25%)
TSLA   426.30 (+1.21%)
NVDA   530.77 (+1.80%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.78 (+2.13%)
GE   6.08 (-1.94%)
AMD   81.90 (+3.04%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.13 (-1.15%)
NFLX   493.46 (+0.57%)
DIS   124.12 (-1.48%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
Log in
NASDAQ:TRIB

Trinity Biotech Stock Forecast, Price & News

$2.06
-0.03 (-1.44 %)
(As of 09/29/2020 12:20 PM ET)
Add
Compare
Today's Range
$2.06
Now: $2.06
$2.13
50-Day Range
$1.68
MA: $2.10
$2.63
52-Week Range
$0.56
Now: $2.06
$3.28
Volume1,000 shs
Average Volume747,599 shs
Market Capitalization$49.52 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Read More
Trinity Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRIB
CUSIPN/A
Phone353-1276-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.43 million
Cash Flow$0.03 per share
Book Value$0.20 per share

Profitability

Net Income$-28,910,000.00

Miscellaneous

EmployeesN/A
Market Cap$49.52 million
Next Earnings Date10/21/2020 (Estimated)
OptionableOptionable
$2.06
-0.03 (-1.44 %)
(As of 09/29/2020 12:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRIB News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions

How has Trinity Biotech's stock been impacted by COVID-19 (Coronavirus)?

Trinity Biotech's stock was trading at $1.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRIB stock has increased by 70.2% and is now trading at $2.06.
View which stocks have been most impacted by COVID-19
.

When is Trinity Biotech's next earnings date?

Trinity Biotech is scheduled to release its next quarterly earnings announcement on Wednesday, October 21st 2020.
View our earnings forecast for Trinity Biotech
.

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) posted its quarterly earnings data on Wednesday, May, 27th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.02. The firm had revenue of $21.18 million for the quarter. Trinity Biotech had a positive return on equity of 7.55% and a negative net margin of 32.47%.
View Trinity Biotech's earnings history
.

Are investors shorting Trinity Biotech?

Trinity Biotech saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 62,300 shares, a decrease of 54.4% from the August 31st total of 136,700 shares. Based on an average daily trading volume, of 710,700 shares, the days-to-cover ratio is currently 0.1 days.
View Trinity Biotech's Short Interest
.

Who are some of Trinity Biotech's key competitors?

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Novavax (NVAX), Opko Health (OPK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Netflix (NFLX), Pfizer (PFE), QUALCOMM (QCOM), Energy Transfer LP Unit (ET) and Exxon Mobil (XOM).

Who are Trinity Biotech's key executives?

Trinity Biotech's management team includes the following people:
  • Mr. Ronan O'Caoimh, Co-Founder, Chairman & CEO (Age 63)
  • Mr. Kevin Tansley, CFO, Company Sec. & Exec. Director (Age 48)
  • Dr. James Walsh, Exec. Director (Age 61)

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

How do I buy shares of Trinity Biotech?

Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $2.06.

How big of a company is Trinity Biotech?

Trinity Biotech has a market capitalization of $49.52 million and generates $90.43 million in revenue each year.

What is Trinity Biotech's official website?

The official website for Trinity Biotech is www.trinitybiotech.com.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.